
|Articles|April 30, 2021
SEC Separation of ADC Brentuximab Vedotin
Author(s)YMC Europe GmbH
The antibody-drug conjugate was separated from its aggregates and fragments in only one run using a YMC-SEC MAB column and varying mobile phases.
The antibody-drug conjugate was separated from its aggregates and fragments in only one run using a YMC-SEC MAB column and varying mobile phases.